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Abstract 
 
Promoting ectopic development of pancreatic beta cells from other cell types is one of the 
strategies being pursued for the treatment of diabetes. To achieve this, a detailed outline of 
the molecular lineage that operates in pancreatic progenitor cells to generate beta cells over 
other endocrine cell types is necessary. Here, we demonstrate that early transient 
expression of the endocrine progenitor bHLH protein Neurogenin 3 (Ngn3) favors the 
promotion of pancreatic beta and delta cell fates over an alpha cell fate, while later 
transient expression promotes ectopic development of all three endocrine cell fates. We 
found that short-term activation of Ngn3 in Xenopus laevis endoderm just after 
gastrulation was sufficient to promote both early and ectopic development of beta and delta 
cells. By examining gene expression changes four hours after Ngn3 activation we identified 
several new downstream targets of Ngn3. We show that several of these are required for 
the promotion of ectopic beta cells by Ngn3 as well as for normal beta cell development. 
These results provide new detail regarding the Ngn3 transcriptional network operating in 
endocrine progenitor cells to specify a beta cell phenotype and should help define new 
approaches to promote ectopic development of beta cells for diabetes therapy. 
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Introduction 
The pancreatic transcriptional program defining development of the various cell types is 
conserved from zebrafish to Xenopus to mammals (Gittes, 2009; Pearl et al., 2009; Tiso et al., 
2009). In Xenopus laevis both early acting genes, such as Ptf1a (Pancreas Specific Transcription 
Factor, 1a) and Pdx1 (Pancreatic and Duodenal Homeobox 1), and later acting genes, such as 
Insm1 (Insulinoma-Associated 1) and Rfx6 (Regulatory Factor X, 6), have been shown to 
operate in a similar fashion as their mammalian counterparts (Afelik et al., 2006; Horb et al., 
2009; Jarikji et al., 2007; Pearl et al., 2011). However, as expected there are some species 
specific characteristics of how the pancreas develops in Xenopus. Morphologically, the dorsal 
and ventral anlagen do not develop as buds off the gut tube as is seen in mammals. During early 
stages the endoderm in Xenopus is used as a nutrient source for the developing embryo and 
tadpole, and as such organization of the endoderm into a gut tube occurs relatively late in 
development (Chalmers and Slack, 1998, 2000). The dorsal pancreatic bud first emerges at stage 
35/36, with the two ventral buds arising slightly later at stage 37/38; these buds fuse by stage 39. 
Molecular genetic differences between these buds has recently been elucidated and shown to 
define the migratory behavior of how they fuse and identify spatial differences in cell fate 
specification (Horb and Horb, 2010; Jarikji et al., 2009). Differentiation of the various endocrine 
cell types occurs in a precisely defined pattern (Kelly and Melton, 2000; Pearl et al., 2009). Beta 
cells differentiate first only in the dorsal pancreatic endoderm with insulin expression first 
detected at stage 32; by stage 46/47 insulin expression can be detected in the ventral portion of 
the pancreas as well. In contrast, expression of glucagon and somatostatin is not pancreas 
specific. They are first expressed in the stomach/duodenum beginning at stage 40, with 
expression in the pancreas not detected until stage 44/45 (Horb and Slack, 2002). The fact that 
the mammalian endocrine transcriptional program is identical in Xenopus, combined with the 
major embryological and molecular benefits of this model, make it an ideal system for 
elucidation of the transcriptional regulatory network controlling development of the various 
pancreatic cell types. 
 
Recent advances in promoting ectopic development of beta cells using defined factors have 
contributed greatly towards a cell-based replacement therapy for diabetes (Borowiak and Melton, 
2009; Horb et al., 2003; Kordowich et al., 2010; Murtaugh, 2007; Pearl and Horb, 2008; 
 4 
Yechoor and Chan, 2010). The goal has been to use pancreatic transcription factors to reprogram 
other cell types, whether differentiated cells or stem cells, into Insulin-expressing endocrine beta 
cells. Many of these studies however, did not result in the promotion of a single cell fate, but 
rather resulted in ectopic promotion of both exocrine and endocrine cell fates. In an effort to 
promote only endocrine cell fates, work has focused on using the endocrine progenitor bHLH 
protein Neurogenin 3 (Ngn3) (Rukstalis and Habener, 2009). This has not however resulted in 
the promotion of insulin producing beta cells, but rather in ectopic development of glucagon 
producing alpha cells (Apelqvist et al., 1999; Grapin-Botton et al., 2001; Schwitzgebel et al., 
2000).  
 
Recently, it was shown that the timing of Ngn3 function during embryonic development was 
essential in regulating its ability to promote one endocrine cell fate over another (Johansson et 
al., 2007), suggesting that it is the competence of the responding cell that is important. In 
agreement with this, it was found that a combination of Ngn3 and other pancreatic factors that 
sequentially contribute to beta cell development was sufficient to convert acinar cells to beta 
cells (Zhou et al., 2008). These results point to the fact that understanding how transcriptional 
information is integrated downstream of Ngn3 to specify the beta cell lineage over other 
endocrine lineages would help in the development of strategies for the directed differentiation of 
functional beta cells from other cell types. 
 
Over the last decade much effort has been placed on elucidating the Ngn3 transcriptional 
regulatory network. Studies have focused on identifying gene expression changes in various 
contexts including, in pancreatic tissue lacking Ngn3 (Petri et al., 2006), in pancreatic tissue or 
stem cells overexpressing Ngn3 (Gasa et al., 2004; Serafimidis et al., 2008) and in endogenously 
isolated Ngn3+ cells (White et al., 2008). Though these studies have identified numerous 
potential targets, in each instance no separation was made to define one endocrine lineage over 
another, and the time points chosen for analysis were long after Ngn3 expression commenced. 
As such the Ngn3 transcriptional network that defines a single endocrine lineage (such as a beta 
cell) over another (such as an alpha cell) has yet to be resolved. 
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In this study we precisely define two different temporal windows in which Ngn3 promotes 
ectopic development of only beta and delta cells in the first instance and beta, delta and alpha 
cells in the second instance. By injecting a Dexamethasone inducible Ngn3 into Xenopus laevis 
embryos we were able to control its activity for a limited duration in the endoderm at specific 
times during development. Our results show that short-term activation (1-4 hours) immediately 
after gastrulation was sufficient to promote ectopic and premature development of pancreatic 
beta and delta cells, but not alpha cells. In contrast, continuous or short-term activation at late 
neurula stages resulted in ectopic development of all three endocrine lineages. Based on these 
phenotypic differences, we identified early downstream targets of Ngn3 involved in beta cell 
development by performing a microarray analysis of early endoderm four hours after Ngn3 
activation. We identified several new genes required not only for Ngn3-induced ectopic beta cell 
development, but also for normal beta cell development. These results provide new information 
regarding the early transcriptional network of beta cells that will help define methods for the 
promotion of beta cells for diabetes therapies. 
 
Results 
Transient Ngn3 misexpression promotes a β cell fate over an α cell fate 
To define the competence window of ectopic beta cell creation by Ngn3, we sought to 
overexpress Ngn3 in naïve endoderm (prior to its endogenous expression) at different times and 
for limited duration. During normal development, endodermal expression of Ngn3 is not detected 
until late tail bud stages, similar to that seen with the zinc finger islet transcription factor 
Insulinoma Associated 1 (Insm1) (Horb et al., 2009). We constructed a Dexamethasone (Dex) 
inducible Ngn3 by fusing the glucocorticoid ligand binding domain (GR) to the C-terminus of 
Ngn3 (hence named Ngn3-GR) and injected it into vegetal blastomeres of Xenopus laevis 
embryos; mainly anterior endoderm was targeted. Continuous activation of Ngn3-GR after 
gastrulation (stages 12-44, 80 hours) promoted ectopic expression of insulin, somatostatin and 
glucagon (Fig. 1B,E,H). However, activation of Ngn3-GR for only four hours after gastrulation 
(stages 12-15) resulted in ectopic expression of only insulin and somatostatin and not glucagon 
(Fig. 1C,F,I). In both cases ectopic expression of endocrine markers was observed throughout the 
liver, stomach and duodenum (black arrowheads, Fig. 1B,E). In rare instances when more 
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posterior endoderm was also targeted we observed ectopic expression of insulin in very posterior 
locations of the intestine (Fig. 1L).  
 
Although the morphology of the pancreas was disturbed, we did find expression of other acinar 
pancreatic markers, protein disulphide isomerase (XPDI) and elastase, in the tissue that 
remained (Fig. 2A-D). In contrast, expression of stomach and liver markers, cathepsin E and hex, 
were reduced (Fig. 2E-H). As we were expressing Ngn3-GR in the anterior endoderm (targeting 
stomach and liver in addition to pancreas) we believe the reduction in these markers was due to 
the fact that Ngn3 was converting prospective liver and stomach into pancreas. Unless specified, 
in all subsequent experiments we activated Ngn3-GR for four hours at stage 12. 
 
To ascertain whether it was the stage of Dex addition that was most critical in defining the 
different effects of Ngn3, we tested short-term activation of Ngn3-GR at later stages. Activation 
for 4 hours at stage 15 (until stage 20) resulted in increased expression of all the three hormones 
as previously seen with continuous activation (data not shown). To determine the minimal time 
of Ngn3 activity required for ectopic promotion of beta cells we activated Ngn3-GR for different 
time periods after gastrulation, and found that activation for as short as one hour (at either stage 
12 or 14) was sufficient to promote ectopic insulin and somatostatin expression over glucagon 
expression (see Fig.7A). These results show that the competence of endodermal cells is indeed 
important for the ability of Ngn3 to promote one endocrine cell type over another. 
 
We believe the differential ability of Ngn3 to promote one cell fate over another is dependent on 
the protein complexes it forms, which is related to its amino acid sequence. To ascertain whether 
mouse and human Ngn3, which are only 55% identical to Xenopus Ngn3, were also able to act in 
a similar fashion to activate the same transcriptional network in promoting beta and delta fates 
over an alpha cell fate we created GR inducible versions of human and mouse Ngn3 and tested 
whether they also acted similarly to Xenopus Ngn3. We found that transient overexpression of 
either mouse or human Ngn3-GR was sufficient to specifically promote ectopic beta and delta 
cell fates and not alpha cell development similar to Xenopus Ngn3 (Fig. 3). The only difference 
we observed was in the amount of mRNA required to generate these phenotypes; human and 
Xenopus Ngn3 required the same amount of mRNA, whereas mouse Ngn3 was more active, 
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requiring 50 times less mRNA; the reason for this difference is unclear. These results suggested 
that the important amino acids required for Ngn3 activity in promoting beta cell differentiation 
are found in the specific amino acids found in all three species. 
 
Ngn3 misexpression prematurely activates insulin via Insm1 and Rfx6 function 
To establish the earliest point when ectopic insulin expression appeared upon Ngn3-GR 
misexpression, we determined at what stage ectopic insulin expression was first detected. Since 
endogenous insulin expression is initially detected in the dorsal pancreas at stage 32 (Pearl et al., 
2009) we examined Ngn3-GR injected embryos at stages 28, 30 and 32 for ectopic expression of 
insulin. By in situ hybridization we found insulin to be expressed 8 hours earlier than 
endogenous (stage 28) in Ngn3-GR injected embryos treated with Dex (Fig. 4E). In addition to 
the timing differences, we also found insulin to be expressed more posteriorly and ventrally in 
the endoderm (Fig. 4H). Using RT-PCR we were able to detect ectopic insulin expression in Dex 
treated embryos as early as stage 24, which is about 12 hours after activation of Ngn3-GR (Fig. 
5A). To eliminate the possibility that the results were due to ectopic transcription of the Insulin 
gene without true beta cell differentiation, we determined if other beta cell markers (Pax4 and 
Sur1) were also ectopically expressed. Pax4 (Paired Box 4) is the beta cell specific transcription 
factor, which has been shown to be both necessary and sufficient for proper differentiation of 
beta cells and not alpha cells (Collombat et al., 2003; Collombat et al., 2009; Sosa-Pineda et al., 
1997). Sur1 (Sulfonylurea Receptor 1; also known as Abcc8, ATP-binding cassette sub-family C 
member 8) is the mature pancreatic beta cell KATP channel, which is critical for proper Insulin 
secretion (Bennett et al., 2010).  In agreement with the fact that the ectopic insulin expressing 
cells were undergoing true differentiation into beta cells, we found ectopic and early expression 
of both pax4 and sur1 throughout the endoderm at stage 32 (Fig. 5B-E). In addition, we also 
found increased expression of the endocrine specific delta cell marker somatostatin at stage 32 
(Fig. 5F,G). These results demonstrate that Ngn3-GR misexpression was sufficient to promote 
premature and ectopic differentiation of beta and delta cells within the early endoderm.  
 
Previous results in Xenopus have shown that endoderm-mesoderm interactions are critical for 
differentiation of pancreatic beta cells (Horb and Slack, 2001). We therefore examined whether 
Ngn3-GR was promoting ectopic beta cell differentiation independent of signals from the 
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mesoderm. We isolated explants of either endoderm alone (WE) or endoderm plus mesoderm 
(WEM) from Ngn3-GR injected embryos at stage 15, grew them until stage 26 and examined for 
ectopic insulin expression by RT-PCR. In agreement with our hypothesis, ectopic insulin 
expression was detected in Dex treated explants of endoderm alone (Fig. 5H). These results show 
that Ngn3 misexpression in the early endoderm directly promoted beta cell differentiation 
independent of signals from the mesoderm, though we cannot exclude the remote possibility of 
earlier mesoderm interactions during the short Dex treatment.  
 
Since we were ectopically expressing Ngn3 (as well as using a hormone inducible version) at an 
earlier time and in ectopic locations than in normal development, it was possible that the 
pathway activated by Ngn3-GR was not the same as that utilized by endogenous Ngn3. To 
ascertain whether this promotion of early and ectopic beta cell differentiation by Ngn3 was 
indeed acting through the endogenous pathway of beta cell development, we examined whether 
this activity was dependent on the proper function of two endocrine specific transcription factors 
Insm1 and Rfx6, both of which have been shown to act downstream of Ngn3 in the endogenous 
pathway of endocrine cell development (Gierl et al., 2006; Horb et al., 2009; Mellitzer et al., 
2006; Pearl et al., 2011; Smith et al., 2010; Soyer et al., 2010). Injection of the antisense Insm1 
morpholinos abolished endogenous insulin expression in the –Dex controls as well as ectopic 
insulin expression in +Dex tadpoles (Fig. 6C,D). Similarly, knockdown of Rfx6 also inhibited 
the ability of Ngn3-GR to promote ectopic beta cell differentiation as well as endogenous insulin 
expression (Figs. 6G,H). Similar results were also observed for both the Insm1 and Rfx6 
morpholinos when insulin expression was analyzed at stage 44 (data not shown). These results 
show that Ngn3 promotion of ectopic and early beta cell differentiation occurred through 
recognized pathways of beta cell differentiation.  
 
Tbx2, Mtg8, Mtg16 and Mtgr1 are needed for ectopic beta cell development 
To identify Ngn3 downstream targets involved in the formation of ectopic beta cells, we 
performed a microarray analysis immediately after activation of Ngn3-GR (Fig. 7B). Briefly, we 
activated Ngn3-GR injected embryos with Dexamethasone for four hours at stage 12 and 
collected embryos at stage 15 and removed all dorsal structures, which included neural tissue and 
ectoderm (Fig. 7C). Total RNA was extracted and hybridized to the Affymetrix Xenopus laevis 
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GeneChip 2.0. Comparison of hybridization results between +Dex and –Dex samples (four 
replicates of ten embryos each) was done using the Robust Multi-Array Average and the 
algorithm EB (Wright and Simon) for statistical analysis.  The results of this analysis yielded 162 
genes upregulated by more than 1.5 fold in the +Dex samples (see Table 1 for a partial list). 
Several transcription factors that were previously identified as downstream of Ngn3 in other 
microarray studies were also identified in our screen, including Insm1 (2.51 fold), Neurogenic 
Differentiation 4 (NeuroD4; 2.12 fold), Zinc Finger Protein 238 (Zfp238; 2.65 fold), and Hairy 
and Enhancer of Split 5 (Hes5; 1.75 fold). In addition, we also found increased expression of 
several other transcription factors that have not been shown to function in beta cell development. 
These include the POU class V protein Oct-25 (Oct25; 2.48 fold), as well as all three Myeloid 
translocation gene family members (Mtg), Mtg8 (2.09 fold), Mtg16 (2.18 fold) and Mtgr1 (2.01 
fold). MTG proteins are known to be important for neural and gut development and they act (to 
repress transcription) as mediators of multiprotein transcriptional networks to promote repression 
of target genes (Amann et al., 2005; Calabi et al., 2001; Koyano-Nakagawa and Kintner, 2005; 
Rossetti et al., 2004). We also found increased expression of other transcription factors, 
including several Hairy and enhancer of split related genes, Hes3 (2.2 fold), Hes5 (1.75 fold), 
Hes9 (1.6 fold) and Hey1 (1.69 fold), and the T-box gene Tbx2 (1.4 fold). 
 
We next sought to confirm differential expression of selected target genes. We examined the 
spatial expression of specific candidate genes in bisected embryos following four hours of Ngn3-
GR activation at two developmental time points, one immediately after activation for four hours 
at stage 15 and the other at stage 20. At stage 15, we confirmed increased expression of tbx2, 
mtg8, hes3 and geminin in the anterior ventral endoderm (Fig. 8A-H dashed circles and arrows). 
Geminin was chosen as a candidate representative of genes that were found increased in the 
microarray, but below 1.5 fold. For oct25 we detected increased expression in the dorsal 
endoderm of the roof of the archenteron (Fig. 8I,J dashed line). We also confirmed increased 
expression of the second MTG family member, Mtgr1 at stage 20 (Fig. 8K,L dashed circles).  
 
We then chose four of these genes (Mtg8, Mtg16, Mtgr1 and Tbx2) and examined whether they 
do indeed function downstream of Ngn3 in the promotion of ectopic beta cells using antisense 
morpholinos. Knockdown of Tbx2, Mtg8, Mtgr1 or Mtg16 in the presence of Ngn3-GR 
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completely abolished promotion of ectopic beta cells by Ngn3 at stage 32 (Fig. 9C,G,K,O). 
Further, injection of Tbx2, Mtg8 or Mtg16 morpholinos alone significantly reduced endogenous 
insulin expression at stage 32, whereas the Mtgr1 morpholino alone had no effect (Fig. 
9D,H,L,P). Analysis at the later stage 44 showed similar results (data not shown). To ensure that 
the results with these morpholinos were specific and not found with unrelated morpholinos we 
examined whether knockdown of Tm4sf3, which we previously showed affected pancreatic bud 
fusion (Jarikji et al., 2009), blocked Ngn3 promotion of ectopic beta cell development. We found 
that the use of the antisense Tm4sf3 morpholino did not affect Ngn3-GR promotion of ectopic 
beta cells (Fig. 10). These data demonstrate that all four candidates are required for the ectopic 
promotion of beta cells by Ngn3, whereas only Tbx2, Mtg8 and Mtg16 are required for 
endogenous beta cell development.  
 
 
Discussion 
Our study demonstrates that transient misexpression of Ngn3 alone shortly after gastrulation can 
direct differentiation of endoderm towards the beta cell lineage, and suggests that Ngn3 control 
of specific endocrine lineages is dependent on cell competence. By activating Ngn3 for a few 
hours at different times we were able to pinpoint specific temporal windows for the ectopic 
creation of beta cells over alpha cells. The observation that activation at stage 12 for four hours 
promoted insulin and somatostatin expression while activation at stage 15 for four hours 
promoted expression of insulin, somatostatin and glucagon argues against an Ngn3 dosage effect 
in the promotion of each endocrine lineage. In addition, we show for the first time that Ngn3 
misexpression is able to promote ectopic formation of beta cells in the stomach and duodenum. 
However, we cannot rule out the possibility that these cells were generated from pancreatic 
progenitors, which then migrated throughout the endoderm. Taken together, our results suggest 
that the spatio-temporal context is crucial for directed and ectopic differentiation of beta cells by 
Ngn3 and possibly for other transcription factors throughout development. Our results agree with 
previous data that had identified different competency windows for Ngn3 function in mice 
(Johansson et al., 2007). However, in that paper temporal windows were evaluated in days rather 
than hours as we show here, and their results mirrored the endogenous temporal expression 
profiles for endocrine hormones. We are the first to demonstrate that transient Ngn3 can be used 
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to directly promote ectopic development specifically of beta and delta cells over alpha cells, and 
earlier than endogenous expression.  
 
The ability to tightly control Ngn3 activity allowed us to isolate immediately early targets of 
Ngn3 and has provided a specific list of genes that function in the beta cell lineage. In particular, 
we have for the first time implicated Mtg8 and Mtg16 in normal pancreas development. 
Although Mtg8 was found to be essential for development of enteroendocrine cells, whether it 
was involved in pancreas development was not reported (Calabi et al., 2001). Previous studies 
have defined a relationship between Mtg proteins and Ngn1 and Ngn2 proteins in Xenopus 
ectoderm and in the chick developing neuronal system whereby Mtg proteins are downstream of 
Ngn proteins, and act as negative feedback regulators of Ngn function (Aaker et al., 2009; Aaker 
et al., 2010; Cao et al., 2002). In relation to pancreas development this would suggest that the 
pathway to beta cells requires short activation by Ngn3 and subsequently its inhibition by Mtg 
proteins. If so, then this would explain why previous studies promoted only alpha cell 
development upon Ngn3 overexpression, since they maintained continuous activation of Ngn3, 
whereas we blocked Ngn3 function shortly after its activation.  
 
Alternatively, it is possible that the interaction between Ngn3 and Mtg proteins in beta cell 
development is not simply to block Ngn3 function, but to promote repression of genes required 
for other endocrine lineages. In agreement with this, a recent study showed that beta cell identity 
is maintained by DNA methylation-mediated repression of Arx by histone modifying enzymes 
(Dhawan et al., 2011). Since the Mtg proteins have been shown to interact with histone 
modifying enzymes and transcriptional corepressors orchestrating protein-protein interactions 
that might cause epigenetic changes for gene downregulation and silencing (Rossetti et al., 
2004), it is possible that Ngn3 both activates transcription of Mtg genes and interacts with the 
Mtg proteins to form complexes that repress key genes like Arx to promote a beta cell fate over 
other endocrine cell fates.  
 
Although Tbx genes are generally known for their role in mesoderm and ectoderm development, 
previous studies have shown that Tbx3, which is thought to act redundantly with Tbx2, acts as a 
transcriptional repressor and plays a role in liver progenitor proliferation and cell-fate 
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determination (Ludtke et al., 2009; Suzuki et al., 2008). Given the proposed model of a common 
pancreas and liver progenitor, the involvement of Tbx2 in early pancreas development would not 
be unexpected. Similar to Tbx3 in liver development, Tbx2 could work downstream of Ngn3 
acting to inhibit expression and/or activity of Arx and promoting proliferation of beta cell 
progenitors. It will be interesting to see if any key pancreatic genes are silenced following 
overexpression of Tbx2 and Mtg genes. 
 
In comparison to previous Ngn3 microarray studies, we found remarkably little overlap with our 
gene list (Gasa et al., 2004; Gasa et al., 2008; Petri et al., 2006; Serafimidis et al., 2008; Treff et 
al., 2006; White et al., 2008). Of the 85 genes listed in Table 1, we found only 8 in common with 
other lists: Insm1, NeuroD4, Irf6, Znf38, Hes5, Stmn3, Hey1 and Mxi1. It is at present unclear 
why there was so little overlap. However, there were two main aspects of our study that were 
different from previous studies. First, we targeted naïve endoderm in vivo at an early stage, while 
previous studies targeted pancreatic tissue in vivo after it had been specified, pancreatic cells in 
vitro or in ES cells in vitro that had been artificially pushed down the endoderm lineage. Second, 
we performed our analysis at a much earlier stage. We isolated and compared endoderm tissue 4 
hours after Ngn3 activation, whereas the earliest time point previously examined was 12 hours. 
Because of these differences we chose to begin our analysis of targets on those genes not 
previously identified. Our results with Mtg8, Mtg16, MtgR1 and Tbx2 are the first to 
demonstrate a role for these genes in pancreas development. 
 
In summary, transient misexpression of Ngn3 in early Xenopus endoderm was sufficient to 
promote ectopic and early development of pancreatic beta cells. The use of Xenopus to define the 
transcriptional network of genes involved in the ectopic creation of beta cells will allow for 
future discovery and elucidation of transcriptional pathways that promote direct beta cell lineage 
development.  
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METHODS 
Antisense morpholino and mRNA injections. Antisense morpholino oligonucleotides were 
designed and produced by Gene Tools LLC to the translation start. Antisense morpholino 
sequences are tbx2 5’-GGTGCATACACAAATCCAGCAGGGA-3’, mtg8 5’-
GGTGCTTGAGATTCCCACCATTCGC-3’, mtgr1 5’-GAT 
AGGGTCCTGGAATCCCAACCAT-3’ and mtg16 5’- 
TGAGTCTGGCATTGTAAACGCTGTA-3’. For mRNA injections, all mRNA was synthesized 
in vitro (Ambion mMessage) and coinjected with 400pg gfp mRNA to verify targeting by 
observing fluorescence in whole embryos or dissected whole guts. For both mRNA and 
morpholinos we injected the two dorsal vegetal blastomeres at the eight cell stage, thus targeting 
the anterior endoderm in most instances. To activate Ngn3-GR protein, embryos were cultured in 
dexamethasone in a final concentration of 10µM in 0.1X MMR.  
 
Microarray Analysis. Embryos injected with Ngn3-GR mRNA were incubated in 
dexamethasone for four hours at stage 12, and then all dorsal structures were removed, leaving 
only the ventral portion of the embryo. Sample sets (4 sets, 10 embryos/set) were kept in 
RNAlater (Ambion) until RNA extraction with TRIzol (Invitrogen) followed by RNeasy Kit 
(Qiagen). RNA quality analysis, cDNA synthesis and hybridization to the Affymetrix GeneChip 
Xenopus laevis Genome 2.0 Array were performed by Genome Quebec. Microarray results were 
analyzed using the expression analysis software FlexArray V1.4.1 (Genome Quebec, Montreal, 
Canada, URL http://genomequebec .mcgill.ca/FlexArray). Data were normalized with Robust 
Multi-Array Average (RMA) and the algorithm EB (Wright and Simon) was used for statistical 
analysis. Microarray data has been deposited in NCBI’s Gene Expression Omnibus under 
accession number GSE29017. All data entries for transcribed locus have been removed from 
Table 1. 
 
Nucleic Acids. The full-length Xenopus laevis ngn3 ORF (NM_001134785) was cloned from 
wild type stage 42 cDNA into the pCS2+ vector. The ORF was then subcloned into a pCS2+ 
vector containing the human glucocorticoid receptor ligand-binding domain (GR) with primers 
SP6 5’-GATTTAGGTGACACTATAG-3’ and Ngn3GrRevClaI 5’-AAGCTATAGGCAT 
CGATACAAGAACTCTA-3’. The GR was fused to the C-terminus of the Xenopus Ngn3 ORF 
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and referred to as Ngn3-GR. GenBank Accession Numbers for mtg8, mtgr1, tbx2, geminin, 
hes3.1 and oct25 are NM_001095596, NM_001086057, NM_001086520, NM_001088403, 
NM_001088503 and NM_001093992, respectively. Whole mount in situ hybridizations were 
performed as described (Horb et al., 2003). 
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Figure Legends 
 
Fig. 1 Differential effects of Ngn3-GR temporal activation. Whole mount in situ hybridization 
of stage 44 whole guts from embryos injected with 1800pg of Xenopus Ngn3-GR mRNA at the 
eight-cell stage. (A,D,G) Control embryos injected with Ngn3-GR mRNA but not treated with 
dex. (B,E,H) Dex treatment from stages 12-44. Increased expression of glucagon (n=14/20), 
insulin (n=23/23) and somatostatin (n=10/10). Arrowheads indicate ectopic insulin expression in 
the liver, stomach and duodenum. (C,F,I) Dex treatment for 4 hours from stages 12-15. 
Increased insulin (n=55/55) and somatostatin (n=22/22) but not glucagon (n=24/24). (J,K) 
Schematics illustrating organs in the whole gut of panels a and b (blue-insulin). (L) Insulin 
expression was detected in rare instances (n=2/50) in posterior areas of the intestine. Pa: 
pancreas. 
 
Fig. 2 Ngn3-GR activation affects anterior gut markers at stage 44. (A-D) Exocrine 
pancreatic markers PDI and elastase are slightly decreased (n=16/16 and n=14/15, respectively). 
(E,F) Stomach marker cathepsin E is significantly reduced (n=14/14). (G,H) Liver and 
duodenum marker hex is slightly decreased (n=7/7). Pancreas is outlined in panels C and D. 
 
Fig. 3 Transient activation of mouse Ngn3-GR and human Ngn3-GR also promoted 
increased insulin expression. (A-D) Embryos injected with 15 pg of mouse Ngn3-GR and 
activated with dexamethasone for four hours at st.12 showed increased insulin (n=10/10) and 
somatostatin (n=7/7) expression. (E,F) Injection of 1800 pg of human Ngn3-GR also caused 
increased insulin expression (n=8/8). Pancreas is outlined in panels A and C. 
 
Fig. 4 Ectopic and early induction of beta cells by Ngn3-GR.  Insulin expression in tadpoles 
that have been sectioned through the dorsal pancreas, with the head removed. (A-D) Control 
injected embryos. Endogenous insulin expression is first detected at stage 32 in a small dorsal 
domain. Endogenous insulin expression in dorsal pancreas (dp) is labeled by arrow in panel C. 
(E-H) Ngn3-GR injected embryos treated with Dex for four hours at stage 12 showed increased 
insulin expression at stage 28 (n=14/18), stage 30 (n=24/30) and stage 32 (n=46/56). (H) Side 
view of stage 34 tadpole treated with Dex showing the extent of ectopic insulin expression (line). 
 
Fig. 5 Ngn3-GR promotes beta cell differentiation (A) RT-PCR for insulin of whole embryos 
at stages 24 and 26. (B,C) Increased pax4 expression detected in Dex treated embryos at stage 32 
(n=15/17). (D,E) Increase in the mature beta cell marker, sur1, at stage 32 (n=19/31) in Dex 
treated embryos. In panel D, arrow indicates nonendodermal expression of sur1. In panel E, 
bracket denotes ectopic expression in endoderm. (F,G) Increase in somatostatin at stage 32 
(n=12/27) in Dex treated embryos.  In panel F, arrow indicates expression of som outside the 
endoderm. In panel G, bracket denotes ectopic expression in endoderm.  (H) RT-PCR at stage 26 
of whole endoderm (WE) and whole endoderm plus mesoderm explants (WEM). Explants were 
dissected at stage 15 following four hours of Ngn3-GR activation, cultured until stage 26 and 
collected for RT-PCR. Twist and FoxF1 are mesoderm markers, which are detected only in the 
WEM explants. 
 
Fig. 6 Insm1 and Rfx6 are necessary for ectopic beta cell promotion by Ngn3-GR. In situ 
hybridizations for insulin expression in all panels. Ngn3-GR mRNA (1800pg) was coinjected 
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with a control mismatch morpholino (mMO) or morpholinos targeting insm1 or rfx6 mRNA, 
activated with Dex for 4 hours and fixed at stage 32. (A,B) Insm1 mMO (20 ng) had no effect on 
endogenous insulin expression in either –Dex (n=8/8) or +Dex (n=12/17) treated embryos. (C,D) 
Injection of Insm1 MOs (2 morpholinos, 20 ng each) abolished endogenous insulin expression in 
–Dex embryos (n=7/7) as well as ectopic insulin expression in +Dex embryos (n=15/15). (E,F) 
Rfx6 mismatch morpholino (25ng) did not affect endogenous or ectopic insulin expression in –
Dex (n=9/9) or +Dex embryos (n=19/41) (G,H) Antisense Rfx6 morpholino (25ng) inhibited 
endogenous insulin expression in -Dex embryos (n=33/33) as well as ectopic insulin expression 
in +Dex embryos (n=46/46). 
 
Fig. 7 Summary of results and schematic diagram of microarray experiment. (A) Summary 
of ectopic expression of endocrine markers. Red boxes indicate time of Dex treatment. 
Activation of Ngn3-GR for 1 or 4 hours beginning at stage 12 resulted in increased insulin and 
somatostatin expression, whereas continuous activation beginning at stage 12 or a 4 hour 
activation beginning at stage 15 resulted in increased expression of insulin, somatostatin and 
glucagon. (B,C) Diagram of microarray experiment. Ngn3-GR mRNA was injected in the two 
dorsal vegetal blastomeres at the eight cell stage. Embryos were grown until stage 12 activated 
with dexamethasone for four hours and confirmed targeting to the anterior endoderm at stage 15 
with GFP fluorescence. All dorsal structures were removed and RNA was extracted immediately 
after.  Four replicates of ten embryos were used to hybridize to the Affymetrix Xenopus laevis 
GeneChip 2.0. 
 
Fig. 8 Validation of microarray data. Following 4 hours of Ngn3-GR activation at stage 12 
candidate genes from the microarray analysis were increased in the endoderm at stage 15: (A,B) 
tbx2 (n=24/24). (C,D) mtg8 (n=21/21). (E,F) hes3 (n=14/42). (G,H) geminin (n=13/44). (I,J) 
oct25 (n=13/13).  And at stage 20: (K,L) mtgr1 (n=9/13). Dashed circles and arrows indicate 
ectopic expression in the anterior endoderm. Dashed line indicates ectopic expression in the 
dorsal endoderm.  
 
Fig. 9 Tbx2, Mtg8, Mtg16 and Mtgr1 function is required for ectopic and endogenous beta 
cell development at stage 32. Tbx2 or Mtg morpholinos (40 ng each) were injected alone or 
with Ngn3-GR mRNA (1800 pg) and activated with Dex for four hours at stage 12 and the 
embryos grown to stage 32 and analyzed for insulin expression. (A-D) Injection of Mtg8 
morpholino blocked ectopic insulin expression by Ngn3-GR (n=20/27). Mtg8 morpholino alone 
inhibited endogenous insulin expression (n=40/77). (E-H) Mtg16 morpholino blocked ectopic 
insulin expression by Ngn3-GR (n=16/20). Mtg16 morpholino alone inhibited endogenous 
insulin expression (n=27/52). (I-L) Mtgr1 morpholino blocked ectopic insulin expression by 
Ngn3-GR (n=28/28). Mtgr1 morpholino alone did not inhibit endogenous insulin expression 
(n=46/59). (M-P) Tbx2 morpholino blocked ectopic insulin expression by Ngn3-GR (n=27/27). 
Tbx2 morpholino alone inhibited endogenous insulin expression (n=20/37). 
 
Fig. 10 Knockdown of Tm4sf3 does not affect Ngn3 promotion of ectopic insulin 
expression.  Ngn3-GR was injected alone or in combination with Tm4sf3 morpholino. Insulin 
expression at stage 32 in (A) control tadpoles; (B) +dex treated tadpoles and (C) in tadpoles 
injected with Tm4sf3 morpholino. (D-F) Insulin expression at stage 44.  
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Table 1 – Partial list of genes upregulated in stage 15 endoderm after fours 
hours of Ngn3-GR activation 
Gene Symbol Unigene ID Gene Title FC 
MGC115198 Xl.16704 Hypothetical protein MGC115198 3.93 
Aif1l Xl.10091 Allograft inflammatory factor 1-like  3.77 
Hba3 Xl.1125 Hemoglobin alpha 3 subunit  3.02 
Slc16a3 Xl.2852 Solute carrier family 16, member 3  2.80 
Ankrd37 Xl.8033 Ankyrin repeat domain 37  2.67 
Btg-x Xl.49497 B-cell translocation protein x  2.67 
Znf238.3 Xl.47150 Zinc finger protein 238.3  2.65 
LOC100158417 Xl.17761 Hypothetical protein LOC100158417 2.59 
Insm1 Xl.14733 Insulinoma-associated 1  2.51 
Oct-25 Xl.48605 POU class V protein oct-25 2.48 
Rfesd Xl.29449 Rieske (Fe-S) domain containing  2.47 
Slc3a2 Xl.3242 Solute carrier family 3 member 2 2.47 
Pdk4 Xl.1717 Pyruvate dehydrogenase kinase, isozyme 4  2.42 
Brn3 Xl.701 POU class 4 homeobox 1 2.25 
Hes3.1 Xl.585 Hairy and enhancer of split 3, gene 1 2.23 
Twsg1 Xl.502 Twisted gastrulation homolog 1  2.21 
Hes3.3 Xl.12067 Hairy and enhancer of split 3, gene 3  2.18 
Mtg16 Xl.14852 Myeloid translocation gene 16 2.18 
Neurod4 Xl.1263 Neurogenic differentiation 4 2.12 
Ptgs2 Xl.33329 Prostaglandin-endoperoxide synthase 2  2.11 
Mtg8 Xl.24705 Myeloid translocation gene 8 2.09 
MGC68579 Xl.34749 Hypothetical protein MGC68579  2.08 
Cer1 Xl.368 Cerberus 1 2.07 
MGC131136  Xl.14925 Hypothetical protein MGC131136  2.05 
Dbndd1 Xl.47316 Dysbindin domain containing 1  2.02 
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Tsc22d3 Xl.12378 TSC22 domain family, member 3  2.01 
Mtgr1 Xl.4960 Myeloid translocation gene Related 1 2.01 
Fgf13 Xl.13859 Fibroblast growth factor 13  1.98 
Chn1 Xl.9113 Chimerin 1.92 
MGC68858 Xl.16456 Hypothetical protein MGC68858  1.90 
Fam101b Xl.56544 Family with sequence similarity 101, member B  1.88 
Bmp7 Xl.3326 Bone morphogenetic protein 7  1.87 
Dll1 Xl.14759 Delta-like 1  1.85 
Elavl3 Xl.1035 ELAV (embryonic lethal, abnormal vision)-like 3  1.84 
Zfand2a Xl.48357 Zinc finger, AN1-type domain 2A  1.82 
Stmn3 Xl.21810 Stathmin-like 3  1.81 
Ndrg4-b Xl.9099 Protein NDRG4-B  1.81 
Hoxd1 Xl.53491 Homeobox D1  1.81 
Esr10-A Xl.9271 Enhancer of split related 10  1.80 
Chst10 Xl.8239 Carbohydrate sulfotransferase 10  1.80 
Atoh7-a Xl.176 Atonal homolog 5a  1.79 
Dlc1 Xl.47179 Deleted in liver cancer 1  1.79 
Rgs1 Xl.31883 Regulator of G-protein signaling 1  1.76 
Irf-6 Xl.1273 Interferon regulatory factor 6 1.76 
Sgk223 Xl.3085 Tyrosine-protein kinase SgK223 1.76 
Hes5.1 Xl.48575 Hairy and enhancer of split 5, gene 1  1.75 
Foxa4-a Xl.441 Forkhead box A4  1.75 
Sat1 Xl.24275 Spermidine/spermine N1-acetyltransferase 1  1.74 
Pik3ip1 Xl.49469 Phosphoinositide-3-kinase interacting protein 1  1.73 
Igf2 Xl.47110 Insulin-like growth factor 2  1.72 
LOC100158359 Xl.55698 Hypothetical protein LOC100158359  1.71 
Pgam1 Xl.11442 Phosphoglycerate mutase 1  1.70 
Hey1 Xl.469 Hairy/enhancer-of-split related with YRPW motif 1  1.69 
 33 
Gadd45g Xl.12125 Growth arrest and DNA-damage-inducible, gamma  1.69 
Stripy  Xl.9206 Stripy  1.69 
Unc119b-A Xl.16769 Protein unc-119 homolog B-A 1.68 
LOC496170  Xl.6950 Hypothetical LOC496170  1.68 
MGC53782 Xl.8440 Similar to enhancer of split related  1.68 
Ccnb1 Xl.4297 Cyclin B1  1.68 
LOC100036864 Xl.50224 Hypothetical protein LOC100036864  1.68 
Mospd1 Xl.26524 Motile sperm domain containing 1  1.67 
Kcnk5 Xl.16485 Potassium channel, subfamily K, member  1.63 
Egln3 Xl.12606 Egl nine homolog 3  1.61 
Unc93a Xl.48437 Unc-93 homolog A  1.60 
Hes9.1-b Xl.12444 hes9.1-b hairy and enhancer of split 9, gene 1 1.60 
Frzb Xl.55584 Frizzled-related protein  1.60 
Dbn1 Xl.49084 Drebrin 1  1.60 
Ppp1r14a Xl.24383 Protein phosphatase 1, regulatory (inhibitor) subunit 14A  1.60 
Tob1 Xl.6421 Transducer of ERBB2, 1  1.59 
Slc7a8 Xl.15844 Solute carrier family 7, member 8  1.59 
Dlc Xl.68 Putative ortholog of delta-like protein C precursor  1.58 
Mespb Xl.53943 Mesoderm posterior homolog B  1.58 
Gramd3 Xl.7613 GRAM domain containing 3  1.57 
Hspc159-a Xl.13396 Galectin-related protein A 1.56 
Ggt1 Xl.18682 Gamma-glutamyltransferase 1  1.56 
Mxi1 Xl.50498 Max Interactor 1 1.56 
LOC100036879 Xl.16140 Hypothetical protein LOC100036879  1.55 
Ppm1k Xl.17302 Protein phosphatase, Mg2+/Mn2+ dependent, 1K  1.53 
Asb5 Xl.48897 Ankyrin repeat and SOCS box-containing 5  1.52 
Ventx1.1 Xl.1420 VENT homeobox 1, gene 1 1.51 
Mcoln2 Xl.1707 Mucolipin 2  1.50 
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Nudt22 Xl.6817 Nudix -type motif 22  1.50 
LOC100158350  Xl.54372 Hypothetical protein LOC100158350 1.50 
MGC115510  Xl.53440 Hypothetical protein MGC115510 1.50 
Arl5b-b  Xl.7620 ADP-ribosylation factor-like 5B 1.50 
